LYMPHOMAS

How to manage Richter transformation: rapid biopsy, targeted combos, and early referral for CAR T or transplant, thus closing the access gap.

Phase 1 data show EB103 delivers 100% complete responses at high dose with manageable toxicity, offering a safer, durable option for high-risk B-cell NHL.

FDA lifts Yescarta limits for relapsed primary CNS lymphoma, expanding CAR T access with phase 1 safety data—what to know about neuro risks.

First-in-human DS3790 trial tests a CD37-targeted ADC for relapsed/refractory B-cell non-Hodgkin lymphoma, aiming to improve response durability and survival.

Phase 2 data show varnim-cel delivers 83% responses with mostly mild CRS and minimal neurotoxicity, boosting CAR T access in India.

A groundbreaking phase 2 trial explores a novel, chemotherapy-free immunotherapy for relapsed indolent B-cell lymphomas, aiming to enhance patient outcomes.

FDA grants orphan drug designation to CTD402, a promising CAR T therapy for relapsed T-cell leukemia and lymphoma, enhancing treatment accessibility.

The FDA approves a larger vial of nelarabine injection, enhancing treatment flexibility for T-cell leukemia in adults and children.

New findings reveal that tafasitamab significantly enhances progression-free survival in relapsed follicular lymphoma when combined with lenalidomide and rituximab.

Marginal zone lymphoma treatment evolves with promising CAR T-cell therapies, addressing unmet needs in aggressive cases and improving patient outcomes.

The FDA designates soficabtagene geleucel as a breakthrough therapy, highlighting its potential in treating relapsed T cell leukemia and lymphoma.

Early findings from the QUILT-106 trial reveal promising outcomes for CD19 CAR-NK cell therapy combined with rituximab in treating Waldenstrom lymphoma.

Epcoritamab shows promising results in improving progression-free survival for patients with relapsed/refractory DLBCL, paving the way for future therapies.

Nivolumab plus AVD shows significant improvement in progression-free survival for advanced Hodgkin lymphoma, establishing it as a preferred treatment option.

Spatial transcriptome sequencing uncovers distinct tumor microenvironment subtypes in angioimmunoblastic T-cell lymphoma, enhancing patient stratification and immunotherapy strategies.

ZUMA-14 trial reveals promising efficacy and safety of axi-cel and rituximab combination therapy for refractory large B-cell lymphoma patients.

The FDA denies accelerated approval for tabelecleucel, highlighting ongoing challenges in treating EBV-positive posttransplant lymphoproliferative disease.

A phase 2 study reveals that combining brentuximab vedotin with gemcitabine shows promising efficacy and safety for relapsed peripheral T-cell lymphoma patients.

Denileukin diftitox transforms CTCL treatment by targeting malignant T cells, offering hope for patients with limited options and severe symptoms.

Patients with Waldenström macroglobulinemia experience comparable outcomes when switching from ibrutinib to zanubrutinib, with improved safety profiles.

A phase 3 study shows tafasitamab combined with lenalidomide and R-CHOP significantly improves outcomes for untreated DLBCL patients.

A groundbreaking study reveals that ultrasensitive ctDNA assays significantly enhance prognosis for large B-cell lymphoma, outperforming traditional PET assessments.

FDA approves mosunetuzumab-axgb for quick subcutaneous treatment of relapsed follicular lymphoma, enhancing patient care and reducing clinic time.

Pirtobrutinib shows significant efficacy and safety in treating relapsed/refractory follicular lymphoma, with promising response rates and durable outcomes.

Duvelisib is now a recommended treatment for cutaneous T-cell lymphoma, highlighting its evolving role in oncology amidst safety concerns.